CAMBRIDGE, MA: Targanta Therapeutics, a biopharmaceutical company seeking FDA approval this year for its lead antibiotic Oritavancin, tapped Russo Partners as its AOR after a competitive bid.
The company hired the agency based on its experience launching antibiotics, such as Zosyn. The work began September 1, said Susan Hager, VP of IR and corporate communications at Targanta. She declined to disclose the budget and the names of the three other agencies that pitched the account.
“They brought a very deep strategic experience and knowledge in the area of antibiotics,” Hager said. The review process took place in August, she added.
Targanta did not have a prior AOR, and had mainly focused on its communications with the investment community, said David Schull, president of Russo.
The firm is handling corporate communications, IR, and media relations for Targanta's involvement at the ICAAC/IDSA conference, considered the leading antibiotic conference in the US, in October, Schull said. Russo has done some work for the company since January.
If the drug, which would be used to treat complicated skin and skin structure infections, is approved on December 8, Russo will also provide launch communications. “It's a... unique opportunity,” Schull said. “We could be part of something that changes the paradigm.”